GR MD 02

Drug Profile

GR MD 02

Alternative Names: Galactoarabino-rhamnogalaturonate; GR-MD-02

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Galectin Therapeutics
  • Developer Galectin Therapeutics; Providence Cancer Center; Providence Health & Services
  • Class Antifibrotics; Antineoplastics; Carbohydrates; Polysaccharides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Hepatic fibrosis; Liver cirrhosis; Plaque psoriasis
  • Phase I Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer
  • Preclinical Breast cancer; Diabetic nephropathies; Fibrosis; Prostate cancer; Pulmonary fibrosis; Renal fibrosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Jun 2017 Galectin Therapeutics receives patent allowance for GR MD 02 for an autoimmune disease in USA
  • 25 Apr 2017 Galectin Therapeutics has patents pending for GR MD 02 in Brazil, Canada, China, Europe, Israel, Korea, Mexico and South Africa
  • 25 Apr 2017 Galectin Therapeutics receives patent allowance for GR MD 02 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top